RxDoctor Payments Data

Ignacio Montes, MD

Hematology & Oncology · Louisville, KYNPI 1568435204

Payments from drug & device makers

$1,046in general payments, 2019–2025

Across 57 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$149
  • Novartis$148
  • AstraZeneca$81
  • Bristol Myers Squibb$52
  • Pfizer$51
  • Eisai Inc.$51
  • plus $515 from 26 others

What the payments were for

  • Food & beverage$97893%
  • Education$444%
  • Gifts$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,046 in reported general payments places this provider in the 10th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$81,271
Medicare patients
299
Services billed
661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate61$555,946
TagrissoOsimertinib Mesylate17$280,054
JakafiRuxolitinib Phosphate14$224,820
KisqaliRibociclib Succinate16$150,737
NinlaroIxazomib Citrate12$146,347
EliquisApixaban128$84,925
XareltoRivaroxaban71$48,032
Imatinib Mesylate12$36,225
Enoxaparin Sodium12$3,492
Ondansetron Hcl41$1,118
Acyclovir76$1,068
Letrozole34$705
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$619
Dexamethasone28$599
Anastrozole18$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$81$835,99978 claims
NovartisKisqali$148$150,73716 claims
PfizerEliquis$51$84,925128 claims
Johnson & JohnsonXarelto$38$48,03271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →